UBP Investment Advisors SA Buys 1,000 Shares of Amarin Co. plc (AMRN)

UBP Investment Advisors SA boosted its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 7.7% during the 1st quarter, HoldingsChannel.com reports. The firm owned 14,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,000 shares during the period. UBP Investment Advisors SA’s holdings in Amarin were worth $291,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Amarin by 0.3% in the 3rd quarter. BlackRock Inc. now owns 3,403,454 shares of the biopharmaceutical company’s stock valued at $55,374,000 after acquiring an additional 11,024 shares during the last quarter. Marshall Wace North America L.P. increased its holdings in shares of Amarin by 175.9% in the 3rd quarter. Marshall Wace North America L.P. now owns 605,553 shares of the biopharmaceutical company’s stock valued at $9,852,000 after acquiring an additional 386,032 shares during the last quarter. Credit Suisse AG purchased a new position in shares of Amarin in the 3rd quarter valued at about $198,000. Enterprise Bank & Trust Co purchased a new position in shares of Amarin in the 1st quarter valued at about $733,000. Finally, AGF Investments Inc. purchased a new position in shares of Amarin in the 4th quarter valued at about $2,735,000. Institutional investors own 48.45% of the company’s stock.

In other Amarin news, insider Steven B. Ketchum sold 55,543 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $21.85, for a total transaction of $1,213,614.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Steven B. Ketchum sold 37,530 shares of the stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $17.17, for a total value of $644,390.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 950,519 shares of company stock valued at $19,527,940. Insiders own 4.08% of the company’s stock.

Shares of NASDAQ AMRN traded down $0.02 during trading hours on Monday, reaching $19.31. The stock had a trading volume of 132,693 shares, compared to its average volume of 6,167,152. The stock has a market cap of $6.24 billion, a PE ratio of -49.36 and a beta of 1.27. The company has a quick ratio of 2.04, a current ratio of 2.40 and a debt-to-equity ratio of 0.35. Amarin Co. plc has a fifty-two week low of $2.35 and a fifty-two week high of $23.33.

Amarin (NASDAQ:AMRN) last announced its earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The company had revenue of $77.30 million during the quarter, compared to analysts’ expectations of $73.87 million. The firm’s revenue for the quarter was up 43.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.08) earnings per share. Sell-side analysts anticipate that Amarin Co. plc will post -0.19 earnings per share for the current year.

AMRN has been the topic of a number of recent analyst reports. BidaskClub downgraded Amarin from a “buy” rating to a “hold” rating in a report on Thursday, March 21st. Zacks Investment Research downgraded Amarin from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. SunTrust Banks reiterated a “buy” rating on shares of Amarin in a report on Monday, January 7th. Citigroup dropped their price objective on Amarin to $20.00 in a report on Tuesday, January 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Amarin in a research report on Monday, April 1st. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $32.17.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2019/04/29/ubp-investment-advisors-sa-buys-1000-shares-of-amarin-co-plc-amrn.html.

Amarin Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Recommended Story: Resistance Level

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.